-1753359608905.webp&w=3840&q=75)
2025 NOSCM | Early-stage Hormone Receptor Positive Breast Cancer: Targeting Therapy to Risk Balanced with Toxicity
Overview
Dr. Reshma Mahtani highlighted the SOFT and TEXT trials, showing a 3.8% absolute five-year DFS benefit for AI over tamoxifen in premenopausal patients. The NEOCARB study suggested carboplatin may be dispensable in early-stage HER2-positive disease.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Reshma L. Mahtani, DO
Date of Release
July 24th, 2025
-1756043706259.webp&w=3840&q=75)
-1756043607111.webp&w=3840&q=75)